Hexarelin and Neuroprotection Research: GHS-R1a CNS Biology, Dopaminergic Pathways and Brain Injury UK 2026

Introduction: Hexarelin at the GHS-R1a–CNS Interface

Hexarelin (His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂) is a synthetic hexapeptide growth hormone secretagogue that acts as a high-affinity, full agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a, also termed the ghrelin receptor). Originally developed as a GH-releasing tool for clinical GH assessment, hexarelin’s biological profile extends substantially beyond the pituitary somatotroph, as GHS-R1a is expressed widely throughout the central nervous system — including in the substantia nigra (SN), ventral tegmental area (VTA), hippocampus, cortex, hypothalamic nuclei, and dorsal raphe.

This broad CNS GHS-R1a expression profile positions hexarelin as a research tool for investigating ghrelin receptor biology in neuroprotection, neuroinflammation, dopaminergic neuron survival, and CNS injury repair contexts that are mechanistically distinct from its pituitary GH-secreting action. The convergence of hexarelin’s GHS-R1a agonism with its documented CD36 interaction — a scavenger receptor expressed on microglia and CNS macrophages — adds an additional immunological dimension to its CNS biology.

GHS-R1a Signalling in Neurons: Intracellular Cascades

GHS-R1a couples primarily to Gq proteins in neurons, activating PLCβ-IP₃-Ca²⁺ release from endoplasmic reticulum stores and PKCδ/ε activation. Secondary coupling to Gi (cAMP suppression) and Gs pathways contributes to the receptor’s pleotropic neuronal signalling. Downstream of Gq/Gi activation in neurons, hexarelin engages:

PI3K-Akt-mTORC1 axis: Neuronal Akt phosphorylation at Ser473 promotes cell survival through Bcl-2/Bcl-xL upregulation, Bad phosphorylation (anti-apoptotic), and mTORC1-S6K1-4E-BP1 activation for protein synthesis and neurite outgrowth. This pathway is the primary neuronal pro-survival arm of GHS-R1a signalling.

ERK1/2–CREB axis: GHS-R1a activates Ras-Raf-MEK-ERK1/2 in neurons, with ERK nuclear translocation phosphorylating CREB at Ser133. CREB-mediated transcription drives BDNF, Bcl-2, and neuroprotective gene expression — a mechanism shared with established neuroprotective growth factors (NGF, NT-3) that converge on the same ERK/CREB node.

AMPK activation: In some neuronal contexts, GHS-R1a agonism activates AMPK — the cellular energy sensor — promoting autophagy flux (LC3-II/p62 readout), mitochondrial biogenesis (PGC-1α), and suppression of mTORC1-mediated neuronal hypertrophy-senescence. The AMPK–autophagy axis is particularly relevant to protein aggregate clearance (Aβ, α-synuclein) relevant to neurodegenerative disease models.

Dopaminergic Neuroprotection: Substantia Nigra Biology

GHS-R1a is expressed on tyrosine hydroxylase-positive (TH+) dopaminergic neurons of the substantia nigra pars compacta (SNpc) — the neuron population selectively lost in Parkinson’s disease. Ghrelin and GHS-R1a agonists have demonstrated neuroprotective effects in multiple dopaminergic injury models, positioning hexarelin as a more potent, peptide-stable research probe for this biology.

MPTP/MPP⁺ Model: MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine) is selectively toxic to SNpc dopaminergic neurons via mitochondrial Complex-I inhibition (MPP⁺ active metabolite), causing ATP depletion, ROS overproduction, and apoptotic cascades. Hexarelin pre-treatment or post-treatment in MPTP-lesioned C57BL/6 mice examines: SNpc TH+ neuron stereological count (unbiased optical fractionator, minimum 6 serial sections per animal); striatal dopamine and metabolites (DOPAC, HVA) by HPLC-ECD; DAT (dopamine transporter) density by autoradiography or [123I]-β-CIT SPECT; motor behaviour (rotarod, pole test, gait analysis by CatWalk); and molecular pathway activation (phospho-Akt, phospho-ERK1/2, Bcl-2, cleaved caspase-3, cytochrome c cytosolic translocation) in SNpc tissue micropunch lysates.

6-OHDA Model: Unilateral medial forebrain bundle (MFB) or intrastriatal 6-hydroxydopamine injection in rats produces hemiparkinsonism with quantifiable asymmetric rotation behaviour (apomorphine-induced contralateral rotation, amphetamine-induced ipsilateral rotation). Hexarelin neuroprotection in 6-OHDA rats uses these rotation endpoints alongside TH+ fibre density in striatum (optical density by immunostaining), SNpc cell count, and neuroinflammatory markers (Iba1+ microglia morphology classification, GFAP+ astrogliosis by immunofluorescence and western blot).

Neuroinflammation: Microglial GHS-R1a and CD36 Biology

Microglial activation — the neuroinflammatory response involving morphological transformation from ramified surveillance state to activated amoeboid phagocytic phenotype — is central to neurodegeneration amplification in Parkinson’s, Alzheimer’s, and traumatic brain injury. GHS-R1a is expressed on microglia, and hexarelin’s CD36 interaction adds a second anti-inflammatory mechanism via CD36-mediated suppression of TLR4/TLR2 signalling.

In BV-2 microglial cell cultures stimulated with LPS (100 ng/mL, TLR4 agonist model of M1 neuroinflammation), hexarelin co-treatment dose-response studies measure: NO production (Griess reagent), ROS generation (DCF fluorescence), TNF-α/IL-1β/IL-6 secretion (multiplex ELISA), iNOS and COX-2 protein expression (western blot), NF-κB p65 nuclear translocation (immunofluorescence or EMSA), and NLRP3/ASC/caspase-1/IL-1β inflammasome complex formation. Pharmacological controls: GHS-R1a antagonist [D-Lys³]-GHRP-6 to confirm receptor specificity; CD36 blocking antibody to dissect CD36 contribution.

Primary microglia isolated from neonatal rat cortex provide a more physiologically representative model than BV-2. Comparison of hexarelin’s anti-neuroinflammatory potency against established reference compounds (minocycline, indomethacin, ghrelin) contextualises the GHS-R1a agonist profile within the neuroinflammation literature.

Traumatic Brain Injury (TBI) Research

Traumatic brain injury involves primary mechanical injury (axonal shearing, contusion, haematoma) followed by secondary injury cascades: oedema (cytotoxic and vasogenic), excitotoxicity (NMDA receptor-mediated Ca²⁺ overload), neuroinflammation (microglial/macrophage activation, cytokine storm), oxidative stress, and mitochondrial dysfunction. The multiple mechanisms implicated in secondary TBI — all involving pathways where GHS-R1a agonism has documented effects — make hexarelin a mechanistically versatile neuroprotection tool for TBI research.

The controlled cortical impact (CCI) model in mice provides reproducible unilateral TBI with quantifiable contusion volume (MRI T2-weighted imaging or cresyl violet histology lesion area × section interval), neurobehavioural deficits (modified neurological severity score, Morris Water Maze spatial learning at 7, 14 days post-injury), and molecular injury cascade quantification. Hexarelin treatment (subcutaneous, commencing within 1–6 hours of CCI) endpoints: contusion volume, oedema (brain water content by wet/dry weight ratio), BBB permeability (Evans blue extravasation, IgG immunostaining), cortical apoptosis (TUNEL, cleaved caspase-3), microglial activation (Iba1 morphometry), astrogliosis (GFAP), and cerebral blood flow (laser Doppler flowmetry).

The fluid percussion injury (FPI) model — hydraulic pressure wave via craniotomy — produces diffuse axonal injury more representative of clinical concussion biology, allowing investigation of hexarelin’s effects on white matter integrity (DTI MRI, myelin MBP/MAG immunostaining), neurofilament phosphorylation (APP-positive axon swellings indicating impaired axonal transport), and neuroinflammatory resolution timeline.

Hippocampal Neurogenesis and Cognitive Biology

Adult hippocampal neurogenesis — the continuous generation of new granule neurons in the dentate gyrus subgranular zone (SGZ) — is regulated by numerous factors including ghrelin/GHS-R1a signalling. GHS-R1a is expressed in the hippocampus (dentate gyrus granule cells, CA1/CA3 pyramidal cells), and ghrelin receptor agonism has been shown to promote neural progenitor proliferation (BrdU+/Ki-67+ cells in SGZ), survival (BrdU+/NeuN+ 28-day post-labelling), and differentiation (doublecortin DCX+ immature neurons) in rodent models.

Hexarelin’s effects on hippocampal neurogenesis are examined in: (1) young naive rodents (baseline neurogenesis capacity); (2) aged rodents (reduced neurogenesis baseline, somatopause context); (3) chronic unpredictable stress (CUS) models (stress-suppressed neurogenesis); and (4) post-TBI recovery (injury-stimulated reactive neurogenesis). Key endpoints: stereological counting of BrdU+/NeuN+ newborn mature neurons (28-day survival post-BrdU injection) in the dentate gyrus; DCX immunostaining for immature neuron pool; BDNF/TrkB expression in hippocampal tissue; spatial learning and memory (MWM, Barnes maze, novel object location) as functional neurogenesis readouts.

GHS-R1a Heterodimer Biology in the CNS

GHS-R1a forms functional heterodimers with dopamine D1R and D2R receptors in striatal and nigral neurons — a mechanistically important interaction that modifies dopaminergic signalling efficacy and downstream neuroprotective responses. GHS-R1a:D1R heterodimers display allosteric cross-talk in which ghrelin/hexarelin binding amplifies cAMP signalling through D1R Gs coupling, potentially enhancing neuroprotective PKA-CREB transcriptional responses. Research dissecting this heterodimer biology uses: FRET/BRET receptor interaction assays in transfected HEK293 cells; bimolecular fluorescence complementation (BiFC); functional receptor interaction measurement via Duolink proximity ligation assay in SNpc sections; and pharmacological dissection (GHS-R1a antagonist + D1R agonist/antagonist combination on ERK/CREB phosphorylation in primary neurons).

Ischaemic Stroke and Cerebral Ischaemia Models

Middle cerebral artery occlusion (MCAO) — transient (45–90 minutes) or permanent filament occlusion in rats or mice — is the reference preclinical stroke model. Hexarelin in MCAO studies examines: infarct volume (TTC staining at 24h; MRI T2-weighted at 72h); neurological deficit (modified Longa scale, grid-walking, cylinder forepaw asymmetry test); BBB integrity (Evan’s blue, claudin-5/occludin western blot); excitotoxicity cascade (glutamate ELISA in CSF, NMDA receptor subunit NR2B expression); mitochondrial function (Complex I/II/III activity in ischaemic cortex); and anti-apoptotic signalling (Bcl-2/Bax ratio, XIAP expression, cytochrome c cytosolic fraction).

Ischaemic preconditioning (sub-lethal ischaemia 48 hours before index MCAO, to induce endogenous neuroprotection) versus hexarelin pharmacological preconditioning comparisons provide mechanistic insight into whether GHS-R1a agonism mimics and/or synergises with endogenous ischaemic tolerance mechanisms.

Research Protocols and Endpoint Standards

Hexarelin dosing in CNS models: Most published preclinical neuroprotection studies use subcutaneous or IP hexarelin at 80–320 µg/kg per injection, with frequency ranging from single administration (acute injury models) to daily (chronic neurodegeneration models over 1–4 weeks). Intracerebroventricular (ICV) injection (2–10 µg per injection) provides CNS-direct delivery for mechanistic studies requiring avoidance of peripheral GHS-R1a effects on GH secretion.

Receptor specificity controls: [D-Lys³]-GHRP-6 (GHS-R1a selective antagonist) at 10-fold molar excess co-administration abolishes on-target hexarelin CNS effects; JMV2959 (a more potent GHS-R1a antagonist) provides an alternative. GHS-R1a knockout (Ghsr−/−) mice as genetic null controls for receptor specificity confirmation.

Molecular endpoint standards: Western blot: phospho-Akt (Ser473), phospho-ERK1/2 (Thr202/Tyr204), phospho-CREB (Ser133), Bcl-2, Bax, cleaved caspase-3/9, BDNF, TH, DAT, iNOS, COX-2, NF-κB p65. RT-qPCR: Bdnf, Gdnf, Bcl2, Bax, Casp3, Tnfa, Il1b, Il6, Iba1, Gfap, Th, Dat, Slc6a3. ELISA: plasma hexarelin (validates systemic exposure), plasma GH, dopamine metabolites, cytokines.

Summary

Hexarelin neuroprotection research spans dopaminergic neuron survival (MPTP/6-OHDA Parkinson’s models), neuroinflammation biology (microglial GHS-R1a and CD36 dual-receptor signalling), traumatic brain injury secondary cascade attenuation (CCI/FPI models), hippocampal neurogenesis promotion, GHS-R1a:D1R heterodimer CNS signalling, and cerebral ischaemia protection (MCAO). Its intracellular neuroprotective mechanisms — PI3K-Akt-Bcl-2 anti-apoptosis, ERK1/2-CREB-BDNF transcription, AMPK-autophagy protein quality control, and NF-κB neuroinflammation suppression — provide a mechanistically coherent framework for its CNS biology. A rigorous endpoint battery spanning stereological neuron counting, motor and cognitive behavioural assays, electrophysiology, molecular pathway analysis, and receptor-specificity controls is required for definitive mechanistic characterisation of hexarelin’s neuroprotective profile.

All information is for research and educational purposes only. Hexarelin is not approved for human therapeutic use and must not be administered to humans.